세계의 POC(Point-Of-Care) 혈당 검사 시장 보고서(2025년)
Point-of-Care Glucose Testing Global Market Report 2025
상품코드 : 1824441
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,444,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,314,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,184,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

POC(Point-Of-Care) 혈당 검사 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.0%로 65억 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 원격의료서비스 확대, 당뇨병 치료에 있어서의 맞춤형 의료의 중시 증가, 당뇨병 관리 프로그램 증가, 포도당 검사 연구개발에 대한 투자 증가, 지속적인 포도당 모니터링의 채택에 기인하고 있습니다. 예측 기간의 주요 동향에는 웨어러블 혈당 모니터링 기기 개발, 포도당 검사에서 스마트폰 연결 통합, 재택 건강 관리 환경에서 POC(Point-Of-Care) 혈당 검사 성장, 포도당 데이터 분석에서 인공지능 채택, 당뇨병 원격 환자 모니터링 확대 등이 포함됩니다.

향후 5년간의 성장률 6.0%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 아일랜드와 중국에서 개발된 지속 포도당 모니터 및 검사 스트립 제조 장비의 가격을 올리고 혈당 조절의 악화와 내분비 진료 비용의 상승을 초래하여 당뇨병 관리에 지장을 초래할 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 넓어질 것입니다.

당뇨병의 유병률 증가는 앞으로 수년간 POC(Point-Of-Care) 혈당 검사 시장의 성장을 이끌 것으로 예측됩니다. 당뇨병은 혈당 수치를 높이는 만성 대사 질환으로 심장, 혈관, 눈, 신장, 신경에 심각한 손상을 입히는 등 장기적인 합병증을 유발합니다. POC(Point-Of-Care) 혈당 검사는 입원 환자의 포도당 수준을 모니터링하는 데 널리 사용되며 혈당 수치의 변화에 대응하는 신속한 치료 판단을 가능하게 하고 당뇨병 관리 및 치료 성적을 향상시킵니다. 예를 들어, NHS 잉글랜드에 따르면 2024년 6월, 잉글랜드에서 당뇨병 예비군으로 확인된 사람의 수는 2023년에는 361만 5,330명으로 올라 2022년 306만 5,825명에서 18% 증가했습니다. 또한 40세 미만의 환자 수는 2022년 17만 3,166명에서 2023년 21만 6,440명으로 25% 가까이 급증했습니다. 따라서 당뇨병 유병률의 상승은 POC(Point-Of-Care) 혈당 검사 시장의 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Point-of-care glucose testing denotes a quality-assured pathology service administered in close proximity to the patient rather than within the conventional confines of a clinical laboratory. Clinicians or individuals employ small handheld units or glucose analyzers, along with testing strips, for glucose testing on whole blood. This approach reduces the duration from specimen collection to result verification, leading to swifter therapeutic intervention, diminished preanalytical errors, and enhanced patient care.

The primary components in point-of-care glucose testing encompass lancet and lancing devices, strips, and meters. Lancets, small sharp instruments, puncture the skin to extract a small blood drop for testing, while lancing devices securely hold the lancet and are activated with a simple button push. These devices facilitate straightforward blood withdrawal and assessment of blood glucose levels using a blood glucose monitor and test strips in point-of-care glucose testing. Testing sites include fingertips and alternate site testing, applied in both type-1 and type-2 diabetes. Various end-users, such as professional diagnostic centers, hospitals and clinics, home care settings, among others, utilize these methods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The point-of-care glucose testing market research report is one of a series of new reports from The Business Research Company that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care glucose testing market size has grown steadily in recent years. It will grow from $4.91 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to growing prevalence of diabetes, increased awareness of diabetes management, expansion of the aging population, rise in healthcare infrastructure, adoption of point-of-care testing.

The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $6.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to expansion of telemedicine services, growing emphasis on personalized medicine in diabetes care, rise in diabetes management programs, increased investment in glucose testing research and development, adoption of continuous glucose monitoring. Major trends in the forecast period include development of wearable glucose monitoring devices, integration of smartphone connectivity in glucose testing, growth of point-of-care testing in home healthcare settings, adoption of artificial intelligence in glucose data analysis, expansion of remote patient monitoring for diabetes.

The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder diabetes management by inflating prices of continuous glucose monitors and test strip manufacturing equipment developed in Ireland and China, resulting in poorer glycemic control and higher endocrinology practice costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of diabetes is expected to drive the growth of the point-of-care glucose testing market in the coming years. Diabetes is a chronic metabolic condition that raises blood glucose levels, leading to long-term complications, including severe damage to the heart, blood vessels, eyes, kidneys, and nerves. Point-of-care glucose testing is widely used to monitor glucose levels in hospitalized patients, enabling quick treatment decisions in response to changes in glycemia and improving diabetes management and therapeutic outcomes. For example, in June 2024, according to NHS England, the number of individuals identified with pre-diabetes in England rose to 3,615,330 in 2023, an 18% increase from 3,065,825 in 2022. Moreover, cases among individuals under 40 surged by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising prevalence of diabetes is fueling the growth of the point-of-care glucose testing market.

The growth of the point-of-care glucose testing market is further fueled by the rising aging population. As demographics shift toward an aging population, characterized by an increasing proportion of elderly individuals, point-of-care glucose testing becomes increasingly crucial. This technology serves essential purposes for older individuals, particularly those at higher risk of diabetes or already diagnosed. The World Health Organization projected that by 2030, one out of every six individuals globally would be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion, and by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Therefore, the growing aging population is a significant driver of the point-of-care glucose testing market.

Product innovation is a key trend gaining traction in the point-of-care glucose testing market, with major companies focused on developing innovative products. For instance, F. Hoffmann-La Roche AG introduced Cobas Pulse in January 2022, a new point-of-care blood glucose monitor designed for healthcare staff. This handheld device includes an automated glucose test strip reader, camera, and touchscreen, housed in a rugged casing that can be disinfected and used across all age groups, including newborns and intensive care patients. The innovation aims to enhance physicians' workflow by integrating Glucommander dosage software and offering downloadable decision-support apps.

Major companies in the point-of-care glucose testing market are also directing their efforts towards developing advanced solutions such as glucose-ketone monitoring sensors. Abbott Laboratories announced in June 2022 the development of a first-of-its-kind biowearable sensor system that continuously monitors glucose and ketones in diabetic patients. This breakthrough device, granted FDA designation, represents a significant advancement in regulatory status and is set to become the most compact and slender monitoring device globally. It integrates seamlessly with Abbott's digital ecosystem, allowing remote monitoring by healthcare professionals.

In August 2024, F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, acquired Point of Care technology from LumiraDx Ltd. for an undisclosed sum. This acquisition enables Roche to enhance its diagnostics portfolio by incorporating a versatile platform that consolidates multiple tests into a single instrument, thereby supporting the growth of decentralized healthcare solutions. LumiraDx Ltd. is a UK-based company specializing in point-of-care diagnostics, particularly glucose testing solutions.

Major companies operating in the point-of-care glucose testing market include F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, TaiDoc Technology Corporation, B. Braun Melsungen AG, Beckman Coulter Inc., Nipro Corporation, Dexcom Inc., Bio-Rad Laboratories Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings plc, Trinity Biotech plc, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc.

North America was the largest region in the point of care glucose testing market in 2024. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Point-of-Care Glucose Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on point-of-care glucose testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for point-of-care glucose testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care glucose testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Point-of-Care Glucose Testing Market Characteristics

3. Point-of-Care Glucose Testing Market Trends And Strategies

4. Point-of-Care Glucose Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Point-of-Care Glucose Testing Growth Analysis And Strategic Analysis Framework

6. Point-of-Care Glucose Testing Market Segmentation

7. Point-of-Care Glucose Testing Market Regional And Country Analysis

8. Asia-Pacific Point-of-Care Glucose Testing Market

9. China Point-of-Care Glucose Testing Market

10. India Point-of-Care Glucose Testing Market

11. Japan Point-of-Care Glucose Testing Market

12. Australia Point-of-Care Glucose Testing Market

13. Indonesia Point-of-Care Glucose Testing Market

14. South Korea Point-of-Care Glucose Testing Market

15. Western Europe Point-of-Care Glucose Testing Market

16. UK Point-of-Care Glucose Testing Market

17. Germany Point-of-Care Glucose Testing Market

18. France Point-of-Care Glucose Testing Market

19. Italy Point-of-Care Glucose Testing Market

20. Spain Point-of-Care Glucose Testing Market

21. Eastern Europe Point-of-Care Glucose Testing Market

22. Russia Point-of-Care Glucose Testing Market

23. North America Point-of-Care Glucose Testing Market

24. USA Point-of-Care Glucose Testing Market

25. Canada Point-of-Care Glucose Testing Market

26. South America Point-of-Care Glucose Testing Market

27. Brazil Point-of-Care Glucose Testing Market

28. Middle East Point-of-Care Glucose Testing Market

29. Africa Point-of-Care Glucose Testing Market

30. Point-of-Care Glucose Testing Market Competitive Landscape And Company Profiles

31. Point-of-Care Glucose Testing Market Other Major And Innovative Companies

32. Global Point-of-Care Glucose Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Point-of-Care Glucose Testing Market

34. Recent Developments In The Point-of-Care Glucose Testing Market

35. Point-of-Care Glucose Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기